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Human and simian immunodeficiency 
viruses (HIV/SIVs) carry a unique set of 
accessory proteins that enhance virus repli-
cation in an optimized manner. These viral 
proteins specific to HIV/SIVs are desig-
nated Vif, Vpx, Vpr, Vpu, and Nef, and are 
functional in certain cell types (Malim and 
Emerman, 2008; Fujita et al., 2010). While 
viruses of the HIV-1 group do not encode 
Vpx, the other HIV-2/SIVs are unable to 
replicate in cells of the myeloid lineage 
such as monocyte-derived dendritic cells 
(MDDCs) and macrophages (MDMs) in 
the absence of Vpx (Fujita et al., 2010). Vpx 
and its structural close relative Vpr are least 
well studied and understood with respect 
to their functional details (Khamsri et al., 
2006; Fujita et al., 2010). Vpx had been 
long thought to be critical for the nuclear 
import of viral DNA in non-dividing cells 
until we and others have independently and 
clearly demonstrated that it is essential for 
the reverse transcription of viral RNA in 
MDDCs (Goujon et al., 2007) and MDMs 
(Fujita et al., 2008; Srivastava et al., 2008). 
Subsequently, these results have been well 
confirmed by the other studies (Goujon 
et al., 2008; Gramberg et al., 2010). We have 
also shown that the deletion of Vpr has 
only a modest (HIV-1) or almost no (HIV-
2) effects on viral replication in MDMs 
(Fujita et al., 2010). On the basis of the new 
findings about HIV/SIV Vpx by us and oth-
ers described above, it has been established 
that there is an innate factor against viral 
reverse transcription in cells of the myeloid 
lineage, and that Vpx counteract the fac-
tor responsible for the inhibition (Sharova 
et al., 2008; Bergamaschi et al., 2009; Kaushik 
et al., 2009). Of a particular note, the Vpx-
mediated enhancement of viral replication is 
also applicable to HIV-1 infection (Goujon 
et al., 2008). Taken all together, it had been 
well predicted that an unidentified fac-
tor present in the myeloid cells is potently 
effective against a wide variety of retrovi-
ruses. Many active HIV/SIV researchers, 
therefore, had focused on its identification 
to better understand the life cycle of primate 
mainly concerned about the restriction of 
Vpx-less HIV-1 replication in myeloid cells 
but not the replication of the other viruses 
with Vpx. 
From the results of Laguette et al. (2011) 
future directions in a short or medium 
range for biological and biochemical char-
acterization of the interaction between 
HIV/SIV Vpx and SAMHD1 are quite evi-
dent and manifold. Most importantly, we 
should perform a systemic genetic analysis 
of non-HIV-1 viruses carrying the vpx gene 
in the presence of SAMHD1. Numerous 
studies on HIV/SIV Vpx thus far conducted, 
both in vitro and in vivo, have indicated that 
Vpx is critical for viruses containing the 
vpx gene (Fujita et al., 2010). In particular, 
monkey model studies have clearly demon-
strated that Vpx is quite necessary for viral 
replication and pathogenesis in individu-
als. Whether SAMHD1 is a natural target 
of HIV/SIV Vpx and is a negative modula-
tor of the viruses should be extensively and 
repeatedly verified. On the other hand, we 
empirically know that vpx-minus HIV-1 can 
replicate, spread, and persist, and survive in 
human populations. If SAMHD1 can deter-
mine or alter the outcome of HIV-1 infec-
tion in humans, how does HIV-1 overcome 
its serious negative effect? Can the activity of 
Vpx be replaced, at least in part, with struc-
turally related HIV-1 Vpr? Alternatively, 
SAMHD1-mediated virus restriction does 
not have much impact on the survival of 
HIV-1 in humans. It is  conceivable that 
immunodeficiency viruses. Finally, Laguette 
et al. (2011) have identified SAMHD1 as the 
myeloid antiviral factor. If confirmed sci-
entifically, SAMHD1 would represent the 
fourth (and most probably the last) major 
restriction factor against HIV/SIV (Table 1). 
SAMHD1 was initially identified in human 
dendritic cell cDNA library as an ortholog of 
a mouse interferon-γ-induced protein that is 
up-regulated in response to viral infections 
(Li et al., 2000; Prehaud et al., 2005; Hartman 
et al., 2007; Zhao et al., 2008). Mutations 
in the gene encoding SAMHD1 have been 
shown to be responsible for 5% of genetically 
inherited Aicardi–Goutières syndrome cases 
characterized by inappropriate activation of 
immune system and aberrant interferon-α 
secretion (Rice et al., 2009). This syndrome 
is a mimic of congenital infection and also 
shows an overlap with systemic lupus ery-
thematosus (Rice et al., 2009). Collectively, 
SAMHD1 is considered to be a regulator of 
cellular intrinsic antiviral response (Rice 
et al., 2009). SAMHD1 has a sterile alpha 
motif (SAM) and an HD domain in tandem. 
SAMs are 65–70 residues in length and can 
serve as protein-interaction modules. The 
HD domain, which is characterized by a 
motif with a doublet of divalent-cation-
coordinating histidine and aspartic acid 
residues, is found in a diverse superfamily 
of enzymes with a potential phosphohydro-
lase activity. In the article of Laguette et al. 
(2011) apart from the identification of a 
novel antiviral cellular factor, authors were 
Table 1 | Restriction factors against HIV/SIV.
Cellular restriction Antiviral activity Counteracting or 
factors  interacting viral proteins
*APOBEC3G/F Induction of lethal mutations in Vif 
 viral genome
CypA, *TRIM5α,  Induction of disordered uncoating? Gag-CA 
and TRIMCyp
*Tetherin Inhibition of virion release Vpu
*SAMHD1 Inhibition of reverse transcription Vpx
*Major restriction factors against HIV/SIV so far reported.
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